MedTrace Logo

Study of MLN8237 in Participants With Advanced Hematological Malignancies

NCT00697346 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-05-31

Study results available
· View outcomes & findings →

Summary

This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.

Conditions

  • B-cell Follicular Lymphoma
  • B-cell Marginal Zone Lymphoma
  • Diffuse Large B-cell Lymphoma
  • B-cell Mantle Cell Lymphoma
  • B-cell Small Lymphocytic Lymphoma
  • B-Cell Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Waldenstrom's Macroglobulinemia
  • Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Enteropathy Associated T-cell Lymphoma
  • NK Lymphoma

Interventions

DRUG

Alisertib

Alisertib (MLN8237) PIC or ECT

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Millennium Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-11
Primary Completion
2016-10-01
Completion
2016-10-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697346 on ClinicalTrials.gov